Title(s):
Associate Professor of Oncology
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blood Transplant, Bone Marrow Transplant, Chronic Myeloid Leukemia, Drug Development, Hematologic Malignancies, Leukemia, Medical Oncology, Myelodysplasia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Education and Experience
Training
- Drexel University College of Medicine (Philadelphia PA)/ (1991)
Residencies
- Strong Memorial Hospital of the (Rochester NY)/ Internal Medicine (1995)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Medical Oncology (1998)
Certifications
- Internal Medicine, American Board of Internal Medicine (2004)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Phone: 410-614-5068
Appointment Phone: 410-955-8964
Fax: 410-614-7437
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Sidney Kimmel Comprehensive Cancer Center
Bio
Expertise
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Blood Transplant
- Bone Marrow Transplant
- Chronic Myeloid Leukemia
- Drug Development
- Hematologic Malignancies
- Leukemia
- Medical Oncology
- Myelodysplasia
- Myelodysplastic Syndrome
- Myeloproliferative Disorders
Research
Research and Publications
Gore, S.D.; Baylin, S.; Sugar, E.; Carraway, H.; Miller, C.B.; Carducci, M.; Grever, M.; Galm, O.; Dauses, T.; Karp, J.E.; Rudek, M.A.; Zhao, M.; Smith, B.D.; Manning, J.; Jiemjit, A.; Dover, G.; Mays, A.; Zwiebel, J.; Murgo, A.; Weng, L.J.; Herman, J.G. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006 Jun 15;66(12):6361-6369.
Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.
Huff, C.A.; Matsui, W.; Smith, B.D.; Jones, R.J. The paradox of response and survival in cancer therapeutics. Blood. 2006 Jan 15;107(2):431-434.
Huff, C.A.; Matsui, W.H.; Douglas Smith, B.; Jones, R.J. Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 2006 Jun;42(9):1293-1297.
Karp, J.E.; Smith, B.D. Exploiting oxidative damage to overcome resistance. Leuk Res. 2006 Oct;30(10):1213-1214.
Karp, J.E.; Smith, B.D. Developmental clinical trials: building one step at a time. Leuk Res. 2006 Jul;30(7):765-766.
Levis, M.; Brown, P.; Smith, B.D.; Stine, A.; Pham, R.; Stone, R.; Deangelo, D.; Galinsky, I.; Giles, F.; Estey, E.; Kantarjian, H.; Cohen, P.; Wang, Y.; Roesel, J.; Karp, J.E.; Small, D. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15;108(10):3477-3483.
Matsui, W.H.; Brodsky, R.A.; Smith, B.D.; Borowitz, M.J.; Jones, R.J. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006 Mar;20(3):458-462.
Davis, A.P.; Sheppard, D.N.; Smith, B.D. Development of synthetic membrane transporters for anions. Chemical Society reviews. 2007 Feb;36(2):348-357.
Karp, J.E.; Ricklis, R.M.; Balakrishnan, K.; Briel, J.; Greer, J.; Gore, S.D.; Smith, B.D.; McDevitt, M.A.; Carraway, H.; Levis, M.J.; Gandhi, V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007 Sep 15;110(6):1762-1769.
Karp, J.E.; Smith, B.D.; Levis, M.J.; Gore, S.D.; Greer, J.; Hattenburg, C.; Briel, J.; Jones, R.J.; Wright, J.J.; Colevas, A.D. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-4473.
Lin, T.L.; Vala, M.S.; Barber, J.P.; Karp, J.E.; Smith, B.D.; Matsui, W.; Jones, R.J. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007 Sep;21(9):1915-1920.
Meng, X.W.; Lee, S.H.; Dai, H.; Loegering, D.; Yu, C.; Flatten, K.; Schneider, P.; Dai, N.T.; Kumar, S.K.; Smith, B.D.; Karp, J.E.; Adjei, A.A.; Kaufmann, S.H. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem. 2007 Oct 12;282(41):29831-29846.
Weir, E.G.; Ali Ansari-Lari, M.; Batista, D.A.; Griffin, C.A.; Fuller, S.; Smith, B.D.; Borowitz, M.J. Acute bilineal leukemia: a rare disease with poor outcome. Leukemia. 2007 Nov;21(11):2264-2270.
Zhao, M.; Rudek, M.A.; He, P.; Hafner, F.T.; Radtke, M.; Wright, J.J.; Smith, B.D.; Messersmith, W.A.; Hidalgo, M.; Baker, S.D. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):1-7.
el-Shami, K.; Smith, B.D. Immunotherapy for myeloid leukemias: current status and future directions. Leukemia. 2008 Sep;22(9):1658-1664.
Karp, J.E.; Smith, B.D.; Gojo, I.; Lancet, J.E.; Greer, J.; Klein, M.; Morris, L.; Levis, M.J.; Gore, S.D.; Wright, J.J.; Garrett-Mayer, E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May 15;14(10):3077-3082.
Matsui, W.; Wang, Q.; Barber, J.P.; Brennan, S.; Smith, B.D.; Borrello, I.; McNiece, I.; Lin, L.; Ambinder, R.F.; Peacock, C.; Watkins, D.N.; Huff, C.A.; Jones, R.J. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008 Jan 1;68(1):190-197.
Warlick, E.D.; O''Donnell, P.V.; Borowitz, M.; Grupka, N.; Decloe, L.; Garrett-Mayer, E.; Borrello, I.; Brodsky, R.; Fuchs, E.; Huff, C.A.; Luznik, L.; Matsui, W.; Ambinder, R.; Jones, R.J.; Douglas Smith, B. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep;32(9):1439-1447.
Bolanos-Meade, J.; Luznik, L.; Muth, M.; Matsui, W.H.; Huff, C.A.; Smith, B.D.; Levy, M.Y.; Kasamon, Y.L.; Swinnen, L.J.; Powell, J.D.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar;43(6):477-480.
Jinawath, N.; Norris-Kirby, A.; Smith, B.D.; Gocke, C.D.; Batista, D.A.; Griffin, C.A.; Murphy, K.M. A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice. J Mol Diagn. 2009 Jul;11(4):359-363.
Karp, J.E.; Flatten, K.; Feldman, E.J.; Greer, J.M.; Loegering, D.A.; Ricklis, R.M.; Morris, L.E.; Ritchie, E.; Smith, B.D.; Ironside, V.; Talbott, T.; Roboz, G.; Le, S.B.; Meng, X.W.; Schneider, P.A.; Dai, N.T.; Adjei, A.A.; Gore, S.D.; Levis, M.J.; Wright, J.J.; Garrett-Mayer, E.; Kaufmann, S.H. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14;113(20):4841-4852.
Smith, B.D.; Karp, J.E. What are the endpoints of therapy for acute leukemias? Old definitions and new challenges. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S296-301.
Ye, Y.; McDevitt, M.A.; Guo, M.; Zhang, W.; Galm, O.; Gore, S.D.; Karp, J.E.; Maciejewski, J.P.; Kowalski, J.; Tsai, H.L.; Gondek, L.P.; Tsai, H.C.; Wang, X.; Hooker, C.; Smith, B.D.; Carraway, H.E.; Herman, J.G. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res. 2009 Nov 1;69(21):8482-8490.
Bolanos-Meade, J.; Smith, B.D.; Gore, S.D.; McDevitt, M.A.; Luznik, L.; Fuchs, E.J.; Jones, R.J. 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2010 Oct 15;In Press.
Brodsky, R.A.; Chen, A.R.; Dorr, D.; Fuchs, E.J.; Huff, C.A.; Luznik, L.; Smith, B.D.; Matsui, W.H.; Goodman, S.N.; Ambinder, R.F.; Jones, R.J. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-2141.
Griffiths, E.A.; Gore, S.D.; Hooker, C.; McDevitt, M.A.; Karp, J.E.; Smith, B.D.; Mohammad, H.P.; Ye, Y.; Herman, J.G.; Carraway, H.E. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma. 2010 Sep;51(9):1711-1719
Griffiths, E.A.; Gore, S.D.; Hooker, C.M.; Mohammad, H.P.; McDevitt, M.A.; Smith, B.D.; Karp, J.E.; Herman, J.G.; Carraway, H.E. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics. 2010 Oct 3;5(7 ).
Kanakry, C.G.; Hess, A.D.; Gocke, C.D.; Thoburn, C.; Kos, F.; Meyer, C.; Briel, J.; Luznik, L.; Smith, B.D.; Levitsky, H.; Karp, J.E. Early lymphocyte recovery following intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 2010 Dec 16.
Karp, J.E.; Blackford, A.; Smith, B.D.; Alino, K.; Seung, A.H.; Bolanos-Meade, J.; Greer, J.M.; Carraway, H.E.; Gore, S.D.; Jones, R.J.; Levis, M.J.; McDevitt, M.A.; Doyle, L.A.; Wright, J.J. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul;34(7):877-882.
Li, L.; Zhao, M.; Navid, F.; Pratz, K.; Smith, B.D.; Rudek, M.A.; Baker, S.D. Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 1;878(29):3033-3038.
Luznik, L.; Bolanos-Meade, J.; Zahurak, M.; Chen, A.R.; Smith, B.D.; Brodsky, R.; Huff, C.A.; Borrello, I.; Matsui, W.; Powell, J.D.; Kasamon, Y.; Goodman, S.N.; Hess, A.; Levitsky, H.I.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-3230.
Pratz, K.W.; Cho, E.; Levis, M.J.; Karp, J.E.; Gore, S.D.; McDevitt, M.; Stine, A.; Zhao, M.; Baker, S.D.; Carducci, M.A.; Wright, J.J.; Rudek, M.A.; Smith, B.D. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010 Aug;24(8):1437-1444.
Smith, B.D.; Kasamon, Y.L.; Kowalski, J.; Gocke, C.; Murphy, K.; Miller, C.B.; Garrett-Mayer, E.; Tsai, H.L.; Qin, L.; Chia, C.; Biedrzycki, B.; Harding, T.C.; Tu, G.H.; Jones, R.; Hege, K.; Levitsky, H.I. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010 Jan 1;16(1):338-347.
Smith, B.G.; Lewin, J.S. Lymphedema management in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2010 Jun;18(3):153-158.
Stein, B.; Smith, B.D. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther. 2010 May;32(5):804-820.
Karp, J.E.; Smith, B.D.; Resar, L.S.; Greer, J.M.; Blackford, A.; Zhao, M.; Moton-Nelson, D.; Alino, K.; Levis, M.J.; Gore, S.D.; Joseph, B.; Carraway, H.; McDevitt, M.A.; Bagain, L.; Mackey, K.; Briel, J.; Doyle, L.A.; Wright, J.J.; Rudek, M.A. Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011 Jan 14;Epub 1/18/11.
Smith, B.D.; Jones, R.J.; Cho, E.; Kowalski, J.; Karp, J.E.; Gore, S.D.; Vala, M.; Meade, B.; Baker, S.D.; Zhao, M.; Piantadosi, S.; Zhang, Z.; Blumenthal, G.; Warlick, E.D.; Brodsky, R.A.; Murgo, A.; Rudek, M.A.; Matsui, W.H. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res. 2011 Jan;35(1):87-94.
Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.
Huff, C.A.; Matsui, W.; Smith, B.D.; Jones, R.J. The paradox of response and survival in cancer therapeutics. Blood. 2006 Jan 15;107(2):431-434.
Huff, C.A.; Matsui, W.H.; Douglas Smith, B.; Jones, R.J. Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 2006 Jun;42(9):1293-1297.
Karp, J.E.; Smith, B.D. Exploiting oxidative damage to overcome resistance. Leuk Res. 2006 Oct;30(10):1213-1214.
Karp, J.E.; Smith, B.D. Developmental clinical trials: building one step at a time. Leuk Res. 2006 Jul;30(7):765-766.
Levis, M.; Brown, P.; Smith, B.D.; Stine, A.; Pham, R.; Stone, R.; Deangelo, D.; Galinsky, I.; Giles, F.; Estey, E.; Kantarjian, H.; Cohen, P.; Wang, Y.; Roesel, J.; Karp, J.E.; Small, D. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15;108(10):3477-3483.
Matsui, W.H.; Brodsky, R.A.; Smith, B.D.; Borowitz, M.J.; Jones, R.J. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006 Mar;20(3):458-462.
Davis, A.P.; Sheppard, D.N.; Smith, B.D. Development of synthetic membrane transporters for anions. Chemical Society reviews. 2007 Feb;36(2):348-357.
Karp, J.E.; Ricklis, R.M.; Balakrishnan, K.; Briel, J.; Greer, J.; Gore, S.D.; Smith, B.D.; McDevitt, M.A.; Carraway, H.; Levis, M.J.; Gandhi, V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007 Sep 15;110(6):1762-1769.
Karp, J.E.; Smith, B.D.; Levis, M.J.; Gore, S.D.; Greer, J.; Hattenburg, C.; Briel, J.; Jones, R.J.; Wright, J.J.; Colevas, A.D. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-4473.
Lin, T.L.; Vala, M.S.; Barber, J.P.; Karp, J.E.; Smith, B.D.; Matsui, W.; Jones, R.J. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007 Sep;21(9):1915-1920.
Meng, X.W.; Lee, S.H.; Dai, H.; Loegering, D.; Yu, C.; Flatten, K.; Schneider, P.; Dai, N.T.; Kumar, S.K.; Smith, B.D.; Karp, J.E.; Adjei, A.A.; Kaufmann, S.H. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem. 2007 Oct 12;282(41):29831-29846.
Weir, E.G.; Ali Ansari-Lari, M.; Batista, D.A.; Griffin, C.A.; Fuller, S.; Smith, B.D.; Borowitz, M.J. Acute bilineal leukemia: a rare disease with poor outcome. Leukemia. 2007 Nov;21(11):2264-2270.
Zhao, M.; Rudek, M.A.; He, P.; Hafner, F.T.; Radtke, M.; Wright, J.J.; Smith, B.D.; Messersmith, W.A.; Hidalgo, M.; Baker, S.D. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):1-7.
el-Shami, K.; Smith, B.D. Immunotherapy for myeloid leukemias: current status and future directions. Leukemia. 2008 Sep;22(9):1658-1664.
Karp, J.E.; Smith, B.D.; Gojo, I.; Lancet, J.E.; Greer, J.; Klein, M.; Morris, L.; Levis, M.J.; Gore, S.D.; Wright, J.J.; Garrett-Mayer, E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May 15;14(10):3077-3082.
Matsui, W.; Wang, Q.; Barber, J.P.; Brennan, S.; Smith, B.D.; Borrello, I.; McNiece, I.; Lin, L.; Ambinder, R.F.; Peacock, C.; Watkins, D.N.; Huff, C.A.; Jones, R.J. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008 Jan 1;68(1):190-197.
Warlick, E.D.; O''Donnell, P.V.; Borowitz, M.; Grupka, N.; Decloe, L.; Garrett-Mayer, E.; Borrello, I.; Brodsky, R.; Fuchs, E.; Huff, C.A.; Luznik, L.; Matsui, W.; Ambinder, R.; Jones, R.J.; Douglas Smith, B. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep;32(9):1439-1447.
Bolanos-Meade, J.; Luznik, L.; Muth, M.; Matsui, W.H.; Huff, C.A.; Smith, B.D.; Levy, M.Y.; Kasamon, Y.L.; Swinnen, L.J.; Powell, J.D.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar;43(6):477-480.
Jinawath, N.; Norris-Kirby, A.; Smith, B.D.; Gocke, C.D.; Batista, D.A.; Griffin, C.A.; Murphy, K.M. A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice. J Mol Diagn. 2009 Jul;11(4):359-363.
Karp, J.E.; Flatten, K.; Feldman, E.J.; Greer, J.M.; Loegering, D.A.; Ricklis, R.M.; Morris, L.E.; Ritchie, E.; Smith, B.D.; Ironside, V.; Talbott, T.; Roboz, G.; Le, S.B.; Meng, X.W.; Schneider, P.A.; Dai, N.T.; Adjei, A.A.; Gore, S.D.; Levis, M.J.; Wright, J.J.; Garrett-Mayer, E.; Kaufmann, S.H. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14;113(20):4841-4852.
Smith, B.D.; Karp, J.E. What are the endpoints of therapy for acute leukemias? Old definitions and new challenges. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S296-301.
Ye, Y.; McDevitt, M.A.; Guo, M.; Zhang, W.; Galm, O.; Gore, S.D.; Karp, J.E.; Maciejewski, J.P.; Kowalski, J.; Tsai, H.L.; Gondek, L.P.; Tsai, H.C.; Wang, X.; Hooker, C.; Smith, B.D.; Carraway, H.E.; Herman, J.G. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res. 2009 Nov 1;69(21):8482-8490.
Bolanos-Meade, J.; Smith, B.D.; Gore, S.D.; McDevitt, M.A.; Luznik, L.; Fuchs, E.J.; Jones, R.J. 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2010 Oct 15;In Press.
Brodsky, R.A.; Chen, A.R.; Dorr, D.; Fuchs, E.J.; Huff, C.A.; Luznik, L.; Smith, B.D.; Matsui, W.H.; Goodman, S.N.; Ambinder, R.F.; Jones, R.J. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-2141.
Griffiths, E.A.; Gore, S.D.; Hooker, C.; McDevitt, M.A.; Karp, J.E.; Smith, B.D.; Mohammad, H.P.; Ye, Y.; Herman, J.G.; Carraway, H.E. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma. 2010 Sep;51(9):1711-1719
Griffiths, E.A.; Gore, S.D.; Hooker, C.M.; Mohammad, H.P.; McDevitt, M.A.; Smith, B.D.; Karp, J.E.; Herman, J.G.; Carraway, H.E. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics. 2010 Oct 3;5(7 ).
Kanakry, C.G.; Hess, A.D.; Gocke, C.D.; Thoburn, C.; Kos, F.; Meyer, C.; Briel, J.; Luznik, L.; Smith, B.D.; Levitsky, H.; Karp, J.E. Early lymphocyte recovery following intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 2010 Dec 16.
Karp, J.E.; Blackford, A.; Smith, B.D.; Alino, K.; Seung, A.H.; Bolanos-Meade, J.; Greer, J.M.; Carraway, H.E.; Gore, S.D.; Jones, R.J.; Levis, M.J.; McDevitt, M.A.; Doyle, L.A.; Wright, J.J. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul;34(7):877-882.
Li, L.; Zhao, M.; Navid, F.; Pratz, K.; Smith, B.D.; Rudek, M.A.; Baker, S.D. Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 1;878(29):3033-3038.
Luznik, L.; Bolanos-Meade, J.; Zahurak, M.; Chen, A.R.; Smith, B.D.; Brodsky, R.; Huff, C.A.; Borrello, I.; Matsui, W.; Powell, J.D.; Kasamon, Y.; Goodman, S.N.; Hess, A.; Levitsky, H.I.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-3230.
Pratz, K.W.; Cho, E.; Levis, M.J.; Karp, J.E.; Gore, S.D.; McDevitt, M.; Stine, A.; Zhao, M.; Baker, S.D.; Carducci, M.A.; Wright, J.J.; Rudek, M.A.; Smith, B.D. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010 Aug;24(8):1437-1444.
Smith, B.D.; Kasamon, Y.L.; Kowalski, J.; Gocke, C.; Murphy, K.; Miller, C.B.; Garrett-Mayer, E.; Tsai, H.L.; Qin, L.; Chia, C.; Biedrzycki, B.; Harding, T.C.; Tu, G.H.; Jones, R.; Hege, K.; Levitsky, H.I. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010 Jan 1;16(1):338-347.
Smith, B.G.; Lewin, J.S. Lymphedema management in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2010 Jun;18(3):153-158.
Stein, B.; Smith, B.D. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther. 2010 May;32(5):804-820.
Karp, J.E.; Smith, B.D.; Resar, L.S.; Greer, J.M.; Blackford, A.; Zhao, M.; Moton-Nelson, D.; Alino, K.; Levis, M.J.; Gore, S.D.; Joseph, B.; Carraway, H.; McDevitt, M.A.; Bagain, L.; Mackey, K.; Briel, J.; Doyle, L.A.; Wright, J.J.; Rudek, M.A. Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011 Jan 14;Epub 1/18/11.
Smith, B.D.; Jones, R.J.; Cho, E.; Kowalski, J.; Karp, J.E.; Gore, S.D.; Vala, M.; Meade, B.; Baker, S.D.; Zhao, M.; Piantadosi, S.; Zhang, Z.; Blumenthal, G.; Warlick, E.D.; Brodsky, R.A.; Murgo, A.; Rudek, M.A.; Matsui, W.H. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res. 2011 Jan;35(1):87-94.
Research Interests
- Myeloid Disorders and Bone Marrow Transplantation
- Acute and Chronic Leukemias
More Info
Languages
- English
Memberships
American Society of Hematology
American Society of Clinical Oncology
American Associate for Advancement of Science
American Society of Clinical Oncology
American Associate for Advancement of Science
Clinical Trials
- Myeloid Disorders and Bone Marr
- Acute and Chronic Leukemias
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts